Mario Brandi

412 total citations
30 papers, 299 citations indexed

About

Mario Brandi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Mario Brandi has authored 30 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Mario Brandi's work include Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mario Brandi is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Breast Cancer Treatment Studies (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Mario Brandi collaborates with scholars based in Italy, United States and Malaysia. Mario Brandi's co-authors include Mario De Lena, Vito Lorusso, Angelo Paradiso, F Marzullo, M. De Lena, Gianfranco Filippelli, Stefania Tommasi, Patrizia Vici, Anita Mangia and Francesco Giotta and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Mario Brandi

27 papers receiving 287 citations

Peers

Mario Brandi

ONCOL

PFM

PRM

L Anselmi Italy

P. Marpicati Italy

David Coeffic France

I. Judson United Kingdom

Hideaki Aoyama Japan

Johanna Sjöström Finland

Roberto Diaz United States

Maria Giuseppa Sarobba Italy

S. Ashley United Kingdom

Salima Kalla France

L Anselmi Italy

Mario Brandi

188 ×1.0

ONCOL

103 ×0.8

87 ×1.2

33 ×0.6

PFM

81 ×2.3

PRM

Citations per year, relative to Mario Brandi Mario Brandi (= 1×) peers L Anselmi

Countries citing papers authored by Mario Brandi

Since Specialization

Citations

This map shows the geographic impact of Mario Brandi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Brandi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Brandi more than expected).

Fields of papers citing papers by Mario Brandi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Brandi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Brandi. The network helps show where Mario Brandi may publish in the future.

Co-authorship network of co-authors of Mario Brandi

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Brandi. A scholar is included among the top collaborators of Mario Brandi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Brandi. Mario Brandi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gadaleta‐Caldarola, Gennaro, Stefania Infusino, Rosa Divella, et al.. (2015). Sorafenib: 10 years after the first pivotal trial. Future Oncology. 11(13). 1863–1880. 37 indexed citations

Vici, Patrizia, Mario Brandi, Francesco Giotta, et al.. (2011). A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Annals of Oncology. 23(5). 1121–1129. 11 indexed citations

Amadori, Dino, Rosella Silvestrini, Mario De Lena, et al.. (2010). Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer. Breast Cancer Research and Treatment. 125(3). 775–784. 19 indexed citations

Vici, Patrizia, Francesco Giotta, Luigi Di Lauro, et al.. (2009). Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.. PubMed. 29(5). 1841–5. 7 indexed citations

Brandi, Mario, Daniela Cabibi, Annamaria Martorana, et al.. (2006). Relationship between thymidylate synthase expression and p53 levels with the treatment of cyclophosphamide, methotrexate, 5-fluorouracil chemotherapy(CMF) versus docetaxel (TXT) in locally advanced carcinoma of the breast. Journal of Clinical Oncology. 24(18_suppl). 10546–10546. 1 indexed citations

Valerio, Maria Rosaria, Manuela G. López, Mario Brandi, et al.. (2004). GRUPPO ONCOLOGICO ITALIA MERIDIONALE. NOVEL ASSOCIATION WITH GEMCITABINE AND DOCETAXEL AS SALVAGE CHEMOTHERAPY IN METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES: RESULT OF A NULTICENTER PHASE II STUDY. Seminars in Oncology. 2004. 9–13. 1 indexed citations

Brandi, Mario, Patrizia Vici, Massimo Lopez, et al.. (2004). Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: Results of a multicenter phase II study1 1On behalf of Gruppo Oncologico Italia Meridionale.. Seminars in Oncology. 31(2 Suppl 5). 13–19. 23 indexed citations

Colucci, Giuseppe, Evaristo Maiello, Vittorio Gebbia, et al.. (1999). 5‐Fluorouracil and levofolinic acid with or without recombinant interferon‐2b in patients with advanced colorectal carcinoma. Cancer. 85(3). 535–545. 2 indexed citations

Colucci, Giuseppe, Evaristo Maiello, Vittorio Gebbia, et al.. (1999). 5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.. PubMed. 85(3). 535–45. 11 indexed citations

10.

Lena, M. De, Vito Lorusso, Mario Brandi, et al.. (1997). Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.. Journal of Clinical Oncology. 15(10). 3208–3213. 28 indexed citations

11.

Brandi, Mario, et al.. (1997). Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer.. PubMed. 16(6B). 3865–9. 7 indexed citations

12.

Lena, M. De, et al.. (1995). CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.. Journal of Clinical Oncology. 13(4). 953–960. 3 indexed citations

13.

Lena, M. De, et al.. (1994). Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).. PubMed. 78(4). 230–5. 2 indexed citations

14.

Lorusso, Vito, Annamaria Catino, Mario Brandi, et al.. (1994). Cyclophosphamide, mitoxantrone and fluorouracil versus cyclophosphamide, mitoxantrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial. 4. 767–772. 4 indexed citations

15.

Lorusso, Vito, et al.. (1993). FEC (FLUOROURACIL, EPIRUBICIN, CYCLOPHOSPHAMIDE) PLUS GRANULOCYTE MACROPHAGE-COLONY-STIMULATING FACTOR (GM-CSF) IN ADVANCED OR INFLAMMATORY BREAST-CANCER - A DOSE-FINDING STUDY. International Journal of Oncology. 3(2). 223–8. 2 indexed citations

16.

Paradiso, Angelo, Stefania Tommasi, Mario Brandi, et al.. (1989). Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer. 64(9). 1922–1927. 55 indexed citations

17.

Lena, Mario De, et al.. (1989). Comparison of CHOP-B vs CEOP-B in ‘poor prognosis’ non-Hodgkin’s lymphomas. A randomized trial. Medical Oncology and Tumor Pharmacotherapy. 6(2). 163–169. 17 indexed citations

18.

Lena, Mario De, et al.. (1988). 4-Demethoxydaunorubicin Administered Orally in Advanced Breast Cancer. Tumori Journal. 74(1). 65–70. 5 indexed citations

19.

Paradiso, Angelo, Mario Brandi, Evaristo Maiello, et al.. (1987). Sequential alternate administration of tamoxifen (TAM) and medroxyprogesterone acetate (MPA) in advanced breast cancer. Clinical-biological randomized study. Journal of Steroid Biochemistry. 28. 112–112. 1 indexed citations

20.

Lena, M. De, et al.. (1987). Randomized trial with two CHOP-B regimens (with doxorubicin or epirubicin) in poor prognosis non-Hodgkin's lymphomas. 24. 223–229. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact